All In Biotech

Drug Trial Radar · NCT04495153

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC Patients

Last checked: Nov 20, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

90

Actual

Start

Oct 13, 2020

Primary completion

Dec 31, 2024

Study completion Dec 2027

Sponsor

Lead sponsor
Candel Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
NYU Langone Health
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the effects of adding CAN-2409 + prodrug for stage III/IV NSCLC patients who are on standard of care first line immune checkpoint inhibitor (ICI) treatment with evidence that the clinical response is inadequate. CAN-2409 is a viral immunotherapy approach that induces tumor-infiltrating T-cells and a consequent PD-L1 up-regulation. A combination of CAN-2409 added to standard of care (SOC) checkpoint inhibitors may lead to improved long-term outcomes for patients with NSCLC who have suboptimal response to ICI therapy.

Conditions

  • Non Small Cell Lung Cancer

Interventions

  • Aglatimagene besadenovecBiological

    Two courses (Cohort 1A and Cohort 2A) or three courses (Cohort 1B and Cohort 2B) via intratumoral injection into an accessible involved tumor site followed by 14 days of prodrug (valacyclovir or acyclovir). For Cohort 1B, the third course is optional. All patients will continue standard of care immune checkpoint inhibitor with or without chemotherapy.

  • ValacyclovirDrug

    Oral, for 14 days following each aglatimagene besadenovec injection

  • Standard of Care anti-PD-1/PD-L1 (ICI)Biological

    Standard of care ICI such as Pembrolizumab, Nivolumab, Durvalumab every 2, 3, 4, or 6 weeks per SOC regimen

  • ChemotherapyDrug

    Standard of care, ongoing maintenance chemotherapy (if applicable) such as Cisplatin/Carboplatin + Pemetrexed or Paclitaxel

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rateTime frame: 12 months
  2. Safety graded by CTCAE version 5.0Time frame: 12 weeks

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • UConn Health

    Farmington, Connecticut

  • Yale University, Yale Cancer Center

    New Haven, Connecticut

  • University of Chicago

    Chicago, Illinois

  • University of Maryland, Baltimore

    Baltimore, Maryland

  • Mayo Clinic

    Rochester, Minnesota

  • NYU Langone Health

    New York, New York

  • The Ohio State University Wexner Medical Center

    Columbus, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Hunter Holmes McGuire VA Medical Center

    Richmond, Virginia

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.